Drug intelligence / Profile preview

SHR-7782

Development stage: Phase 1
Lead developer: Suzhou Suncadia Biopharmaceutical
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SHR-7782 is a proprietary antibody-drug conjugate (ADC) designed to specifically bind to nectin-4, a tumor cell surface antigen, thereby enabling immune-mediated elimination of tumor cells. It is being developed as a therapeutic biological product for the treatment of advanced solid tumors, including advanced malignant cancer. There are currently no approved drugs with an identical mechanism or for the same target, and clinical trials are in the first phase of development. The drug has been independently developed by Chinese biopharmaceutical firms.

Targets

PVRL4 (Nectin cell adhesion molecule 4)

Beyond the preview

Go deeper on SHR-7782.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-7782.

Explore the full profile